Table 2.
CI analysis of VER-155008 combined with bortezomib at a nonconstant ratio in MM.1S cells
| Bortezomib (nmol/L) | VER-155008 (μmol/L) | Effect | CI | Description |
|---|---|---|---|---|
| 2.5 | 1 | 0.224869 | 0.82237 | Synergism |
| 5 | 1 | 0.404416 | 0.60749 | Synergism |
| 2.5 | 2.5 | 0.439279 | 0.88300 | Synergism |
| 5 | 2.5 | 0.553167 | 0.75474 | Synergism |
| 2.5 | 5 | 0.673446 | 0.94774 | Synergism |
| 5 | 5 | 0.642069 | 1.08376 | Antagonism |
Analysis was conducted using the CompuSyn software (ComboSyn, Inc.). Descriptions are based on CI values and the recommendations of CompuSyn: < 1.0, synergism; > 1.0, antagonism. The enzyme-labeling instrument 450 measured the numbers in column effect after 24 h in MM.1S cells with each indicated treatment